Endri Mauro

Treviso, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.

Journal: Bone marrow transplantation

Published: May 27, 2026

Real-life management of 476 older adults with Philadelphia-negative acute lymphoblastic leukemia: a Campus ALL study.

Real-life management of 476 older adults with Philadelphia-negative acute lymphoblastic leukemia: a Campus ALL study.

Journal: Haematologica

Published: June 25, 2025

Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.

Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.

Journal: Annals of hematology

Published: May 30, 2025

Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.

Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.

Journal: Bone marrow transplantation

Published: March 16, 2025

New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers.

New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers.

Journal: Journal of clinical medicine

Published: December 13, 2024

Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.

Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.

Journal: Haematologica

Published: May 15, 2024

Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].

Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].

Journal: Leukemia research

Published: February 27, 2022

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.

Journal: Leukemia research

Published: October 24, 2021

Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.

Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 09, 2021

Rituximab as second-line therapy after new direct antiviral agents in peripheral neuropathy Hepatitis C Virus related: always correct therapeutic approach?

Rituximab as second-line therapy after new direct antiviral agents in peripheral neuropathy Hepatitis C Virus related: always correct therapeutic approach?

Journal: Acta gastro-enterologica Belgica

Published: December 15, 2020

Hepatitis C virus-related cryoglobulinemic vasculitis.

Hepatitis C virus-related cryoglobulinemic vasculitis.

Journal: Minerva medica

Published: November 17, 2020

Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.

Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.

Journal: Hematological oncology

Published: November 01, 2020

Showing 1-12 of 38

Last Updated: 09/26/2026